Wang Deping, Guo Changxiu, Kong Tingting, Mi Guangxi, Li Jiantao, Sun Yuhan
Department of Endocrinology and Metabolism, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
Department of Otolaryngology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
Oncol Lett. 2019 Mar;17(3):3355-3361. doi: 10.3892/ol.2019.10011. Epub 2019 Feb 4.
The present study aimed to examine whether serum microRNA (miR)-22 may be considered a potential biomarker to differentiate patients with papillary thyroid cancer (PTC) from healthy controls. Reverse transcription-quantitative polymerase chain reaction demonstrated that serum miR-22 expression was significantly enhanced in patients with PTC compared with in patients with benign thyroid nodules (BTN) and healthy controls. The expression levels of miR-22 were also increased in the thyroid tissue of patients with PTC compared with in patients with BTN. In addition, increased miR-22 in the serum of patients with PTC was positively associated with metastasis. Furthermore, miR-22 serum levels were increased in patients with PTC and the B-Raf proto-oncogene, serine/threonine kinase V600E mutation. Meanwhile, compared with patients with PTC and ≤1 ng/ml thyroglobulin (Tg)-fine needle aspiration biopsy (FNAB), serum miR-22 was significantly enhanced in patients with PTC and 1-10 ng/ml Tg-FNAB and >10 ng/ml Tg-FNAB. A receiver operating characteristic analysis demonstrated that serum miR-22 distinguished patients with PTC from patients with BTN and healthy controls. In conclusion, to the best of our knowledge, the present study was the first to demonstrate that upregulation of serum miR-22 may be used as a potential biomarker to distinguish patients with PTC from healthy controls.
本研究旨在探讨血清微小RNA（miR）-22是否可被视为区分甲状腺乳头状癌（PTC）患者与健康对照者的潜在生物标志物。逆转录定量聚合酶链反应表明，与良性甲状腺结节（BTN）患者和健康对照者相比，PTC患者血清miR-22表达显著增强。与BTN患者相比，PTC患者甲状腺组织中miR-22的表达水平也有所升高。此外，PTC患者血清中miR-22升高与转移呈正相关。此外，PTC患者以及存在B-Raf原癌基因丝氨酸/苏氨酸激酶V600E突变的患者血清miR-22水平升高。同时，与PTC且甲状腺球蛋白（Tg）-细针穿刺活检（FNAB）≤1 ng/ml的患者相比，PTC且Tg-FNAB为1-10 ng/ml和>10 ng/ml的患者血清miR-22显著升高。受试者工作特征分析表明，血清miR-22可区分PTC患者与BTN患者及健康对照者。总之，据我们所知，本研究首次证明血清miR-22上调可作为区分PTC患者与健康对照者的潜在生物标志物。
